An update on approaches to the development of respiratory syncytial virus (RSV) and parainfluenza virus type 3 (PIV3) vaccines

Clicks: 360
ID: 118352
1994
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
RSV and PIV3 are responsible for about 30% of severe viral respiratory tract disease leading to hospitalization of infants and children. For this reason, there is a need to develop vaccines effective against these viruses. Since these viruses cause severe disease in early infancy, vaccines must be e …
Reference Key
br1994virusan Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Murphy BR;Hall SL;Kulkarni AB;Crowe JE;Collins PL;Connors M;Karron RA;Chanock RM;;
Journal virus research
Year 1994
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/8030364
Keywords
vaccination immunity National Center for Biotechnology Information NCBI NLM MEDLINE Mice review animals clinical trials as topic humans pubmed abstract nih national institutes of health national library of medicine adult Infant newborn Antibodies respiratory syncytial viruses / immunology* sigmodontinae vaccines r m chanock b r murphy viral / biosynthesis viral / immunology human / immunology* influenza human / prevention & control respiratory syncytial virus infections / prevention & control maternally-acquired attenuated parainfluenza virus 3 anti-idiotypic / immunology pan troglodytes pmid:8030364 doi:10.1016/0168-1702(94)90059-0 s l hall iscoms influenza vaccines* / immunology influenza vaccines* / toxicity peptide fragments / chemical synthesis peptide fragments / immunology synthetic viral vaccines* / immunology viral vaccines* / toxicity

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.